Brensocatib significantly reduced the rate of pulmonary exacerbations and slowed lung function decline in patients with ...

The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized rate of pulmonary exacerbations by around 20% compared with ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Incorporated announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic ...

This finding not only provides a new treatment option for patients with bronchiectasis but also lays a solid foundation for the development of more targeted therapies in the future. This study ...

Pope Francis’ doctor is sharing new details about the 88-year-old pontiff's final hours, including why Francis wasn’t ...

The following is a summary of "Bronchiectasis In Patients With Inflammatory Bowel Diseases – Prevalence, Predictors, And ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Pope Francis died of a cerebral stroke that put him into a coma, leading to heart failure, the Vatican has announced. The ...

"Brensocatib has the potential to transform the treatment landscape for bronchiectasis and we were pleased to receive the FDA acceptance of our NDA with priority review even earlier than ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

At 88 years old, Pope Francis died, the Vatican announced on April 21. His cause of death was a cerebral stroke which put him ...